Omega-3 fatty acids, huperzine A, and synthetic coenzyme Q10 have been proven in clinical trials to be no better than placebo (i.e., like a sugar pill) for Alzheimer's disease patients, according ...

An existing drug for HIV could double as a preventative therapy for Alzheimer’s disease, according to researchers. NRTIs (nucleoside reverse transcriptase inhibitors) are antivirals that are ...

A recent study hints that individuals in the early stages of Alzheimer's may have difficulties with turning while walking. Health experts from University College London (UCL) used virtual reality ...

A cholinergic agonist first developed in the 1990s for Alzheimer’s disease, xanomeline, was approved last year in combination with trospium chloride, a side-effect blocker, for the treatment of ...

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease. advertisement What to know about Lumipulse.

Alzheimer’s disease now affects more than seven million people in the U.S., and nearly four in five Americans say they would want to know if they have it before symptoms emerge. This data comes ...

With the number of Americans living with the disease steadily increasing, scientists predict that 13.8 million will have Alzheimer’s by 2050, or 16% of the US population over the age of 65 ...

Disproven alternative therapies for treating cognitive symptoms in Alzheimer's disease include omega-3 fatty acids, huperzine A, and synthetic coenzyme Q10, according to the Alzheimer's Association.

An emerging class of treatments may provide a new way of treating Alzheimer’s. Anti-amyloid medications work inside the brain to prevent Alzheimer’s disease from progressing.

Alzheimer's affects an estimated 7.2 million people in the U.S. age 65 and over, with 74 percent of those patients aged 75 or older, according to the Alzheimer's Association 2025 Disease Facts and ...

The Food and Drug Administration (FDA) cleared the first blood test on Friday to help diagnose Alzheimer's disease. The test, manufactured by Fujirebio Diagnostics, is for those aged 55 and older ...

A new report suggests up to 7.2 million Americans ages 65 and older are living with Alzheimer’s disease, an increase of about 300,000 cases of the mind-robbing disease from a year ago.. The ...